Literature DB >> 9179684

Percutaneous treatment of transitional cell carcinoma of the upper urinary tract.

H Okada1, H Eto, I Hara, M Fujisawa, G Kawabata, N Yamanaka, S Arakawa, S Kamidono.   

Abstract

BACKGROUND: We evaluated the long-term effect of percutaneous resection in 2 Japanese patients with transitional cell carcinoma of the renal pelvis, and reviewed the medical literature on similar patients, to determine the appropriate indications for percutaneous treatment of transitional cell carcinoma in the upper urinary tract.
RESULTS: Indications for endoscopic resection in the 2 patients were renal insufficiency and unsuitability for major open surgery. The patients had no recurrence during follow-up. Seven previous reports described percutaneous resection of upper urinary tract transitional cell carcinoma in 82 patients. Although 72.6% of the patients were successfully treated by percutaneous resection, half of the patients with grade 3 carcinoma developed recurrence.
CONCLUSION: These results, together with those of the 7 published reports, suggest that percutaneous resection should be limited to selected patients with low-grade transitional cell carcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9179684     DOI: 10.1111/j.1442-2042.1997.tb00158.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  3 in total

Review 1.  Endoscopic Treatment of Upper Tract Urothelial Carcinoma.

Authors:  Daniel P Verges; Costas D Lallas; Scott G Hubosky; Demetrius H Bagley
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

2.  Comprehensive management of upper tract urothelial carcinoma.

Authors:  Georgios Koukourakis; Georgios Zacharias; Michael Koukourakis; Kiriaki Pistevou-Gobaki; Christos Papaloukas; Athanasios Kostakopoulos; Vassilios Kouloulias
Journal:  Adv Urol       Date:  2008-12-10

Review 3.  Minimally invasive management of upper tract urothelial carcinoma.

Authors:  Fadi N Joudi; Curtis N Crane; Michael A O'Donnell
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.